Partnership with an OTC company!!! Great!!!Concordia partnered with a little OTC company and our freakin Dumbo is happy!!!! THat's probably the best he will get with no upfront payment!! Why the did not partnered with a major pharma? FTS-Salirasib is a known molecule against Ras for a decade now. Combination strategy for is well documented since 2004. And all they were able to get is a little partnership with an OTC company. Now our Dumbo sees it as a positive news!!!! Way to go Dumbo!!!! For me it is in line with their "encouraging" results in pancreas an lung cancers. Since 4601 is likely to share the same mechanism of action, because both molecules are based on the farnesyl group necessary to anchor Ras protein inside the cell membrane. It is likely that the hopes for 4601 are the same as for Salirasib and Concordia. Small partnership or small takeover by a small "Canadian pharma" to get the rights on this small molecule. Think small!!!!!
Roche and AstraZeneca were aware of FTS-Salirasib since the begining of the century. Farnesylthiosalycilic acid is an easily available molecule. So they made their own tests with it. They also know that 4601 is very similar. So since all that time they were not interested to strike any deal. So our Dumbo can dream of huge takeover scenario. But based on the known facts. It seems that these farnesylated Ras inhibitor will have the same fate as the Farnesyl transferase inhibitors (FTis). These molecules are showing good activity in pre-clinical testing, but the results in human are not as good. Concordia "encouraging" results are a good proof of that. No breakthrough there. So forget the revolution in cancer treatment. That's why Concordia partnered with an OTC company insted of a big deal with a big pharma, and that's why Thallion's stock price is at 0.20$, and that's probably why the strategic review will take more time. Thallion clearly needs to come up with results that will change the perception about farnesylated inhibitors. Until they can provide these results it will remain very speculative. In my opinion the GBM interim results will be their last chance to change the perception with their actual cash. So it is a big gamble.